Examples of using Prolonged-release tablets in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Efficacy was maintained in 87 of 103 patients switched to pramipexole prolonged-release tablets.
SIFROL 0.26 mg and 0.52 mg prolonged-release tablets are white to off-white, of round shape, and have bevelled edges.
Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine.
SIFROL 1.05 mg, 1.57 mg, 2.1 mg,2.62 mg and 3.15 mg prolonged-release tablets are white to off- white and of oval shape.
The 3 mg prolonged-release tablets are round and green, hard tablets, debossed with 3MG on one side and 503 on the other side.
What Circadin looks like andcontents of the pack Circadin 2 mg prolonged-release tablets are available as white to off-white round bi-convex shaped tablets. .
The prolonged-release tablets must not be chewed, divided or crushed, and should be taken around the same time every day.
What Emselex looks like andcontents of the pack Emselex 7.5 mg prolonged-release tablets are round, convex white tablets and are debossed with“ DF” on one side and“ 7.5” on the other.
SIFROL prolonged-release tablets is a specially designed tablet from which the active ingredient is gradually released, once the tablet has been ingested.
What Emselex looks like andcontents of the pack Emselex 15 mg prolonged-release tablets are round, convex light peach tablets and are debossed with“ DF” on one side and“ 15” on the other.
Prolonged-release tablets- EU/ 1/ 07/ 395/ 065- CLEAR 28 prolonged-release tablets- EU/ 1/ 07/ 395/ 001- CLEAR 30 prolonged-release tablets- EU/ 1/ 07/ 395/ 002- CLEAR 49 prolonged-release tablets- EU/ 1/ 07/ 395/ 003- CLEAR 56 prolonged-release tablets- EU/ 1/ 07/ 395/ 004- CLEAR 98 prolonged-release tablets- EU/ 1/ 07/ 395/ 005- CLEAR.
It is available as immediate- release tablets(0.088 mg, 0.18 mg, 0.35 mg,0.7 mg and 1.1 mg) and prolonged-release tablets 0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg and 3.15 mg.
Then take your Oprymea prolonged-release tablets next morning and do not take any more Oprymea(immediate release)tablets. .
Patients already on a regimen of Viramune immediate-release twice daily in combination with other antiretroviral agents canbe switched to Viramune 400 mg prolonged-release tablets once daily in combination with other antiretroviral agents without a lead-in period of Viramune immediate-release.
Envarsus 0.75 mg prolonged-release tablets are oval, white to off-white uncoated tablet, debossed with“0.75” on one side and“TCS” on the other side.
Accordingly, as anaemia, granulocytopenia, anaphylactic reaction, jaundice, Stevens-Johnson Syndrome/toxic epidermal necrolysis(which may be fatal), angioedema, decreased blood phosphorus andincreased blood pressure during maintenance phase with Viramune prolonged-release tablets were not seen in study 1100.1486 the frequency category was estimated from a statistical calculation based on the total number of patients exposed to nevirapine prolonged-release in the maintenance phase of the randomised controlled clinical study 1100.1486 n= 505.
Oprymea 2.62 mg prolonged-release tablets are white or almost white, round(diameter 10 mm), slightly biconvex tablets engraved with P13 on one side and 262 on the other side, with bevelled edges and possible spots.
Important information about some of the ingredients of Ranexa The 500 mg prolonged-release tablets contain the azo colouring agent E110, and the 750 mg prolonged-release tablets contain the azo colouring agent E102.
Alternatively, 50 mg prolonged-release tablets for paediatric patients aged 3 years and older are available for a once daily administration after the lead-in period please refer to the Summary of Product Characteristics of Viramune 50 mg prolonged-release tablets.
Patients should beinstructed that they should not begin Viramune prolonged-release tablets until any rash that has occurred during the 14-day lead-in period of Viramune immediate-release has resolved.
SIFROL 0.26 mg prolonged-release tablets SIFROL 0.52 mg prolonged-release tablets SIFROL 1.05 mg prolonged-release tablets SIFROL 1.57 mg prolonged-release tablets SIFROL 2.1 mg prolonged-release tablets SIFROL 2.62 mg prolonged-release tablets SIFROL 3.15 mg prolonged-release tablets.
The additional studies showed that the prolonged-release tablets were as effective as the immediate- release tablets in treating Parkinson's disease.
Week treatment initiation pack contains 21 prolonged-release tablets in 3 packages: the package marked"Week 1" contains 1 blister of 7 tablets of 0.26 mg, the package marked"Week 2" contains 1 blister of 7 tablets of 0.52 mg, the package marked"Week 3" contains 1 blister of 7 tablets of 1.05 mg.
Cartons with 10, 20, 28, 30, 50, 56, 60, 90, 98, 100,140(10x14) prolonged-release tablets Calendar packs of 28 and 98 prolonged-release tablets Unit dose pack of 50 x 1 prolonged-release tablets.
The safety and efficacy of pramipexole prolonged-release tablets in the treatment of Parkinson's disease was evaluated in a multinational drug development program consisting of three randomised, controlled trials.
Thereafter your child will be switched to Viramune prolonged-release tablets once a day and your child's doctor will decide the right dose and prolonged-release tablet strength based either on your child's weight or body surface area.
In a clinical trial with healthy volunteers, where SIFROL prolonged-release tablets were titrated faster(every 3 days) than recommended up to 3.15 mg pramipexole base(4.5 mg of salt) per day, an increase in blood pressure and heart rate was observed.
Coated tablet>< Modified-release tablet>< Prolonged-release tablet.
For Parkinson's disease, the starting dose is either one 0.088-mg immediate-release tablet three times a day orone 0.26-mg prolonged-release tablet once a day.
